Azure Biosystems Receives Seal of Quality Award

Press Releases

Dublin, Calif. – August 5, 2022 – Azure Biosystems has earned its first SelectScience® Seal of Quality award, in recognition of outstanding feedback received from scientists globally.

The Azure cSeries Gel Imaging Systems have been awarded a Bronze Seal of Quality in recognition of having received over 50 reviews from scientists globally, with an impressive overall rating of 4.9 out of 5 stars.

bronze seal of quality

Seals of Quality recognize the top 0.1% of products that consistently get the highest customer review ratings on SelectScience®, a leading independent laboratory technology website, and are designed to help scientists see, at a glance, the instruments and services their peers love the most.

There are four levels of Seal of Quality: Platinum, Gold, Silver, and Bronze, differentiated by how many reviews a product has received and its overall average rating. This marks the first Seal of Quality to be awarded to Azure Biosystems.

“I would like to take this opportunity to thank all our reviewers around the world for sharing their valuable opinions and also to congratulate Azure Biosystems, who have been recognized by the people who matter most, their customers,” said SelectScience CEO, Kerry Parker.

The Azure Imaging Systems (which have replaced the Azure cSeries Imaging Systems) provide fast, flexible imaging for Western blots, gels, and more. Systems are available with multiple imaging modes including chemiluminescence, visible light, fluorescence and laser-based near infrared imaging. Compared to the original cSeries, the Azure Imaging Systems include a new 9 megapixel camera for even higher resolution and faster imaging and offer four-channel detection for multicolor and quantitative fluorescent Western blotting. Visit Azure Biosystems to learn more about the Azure Imaging Series.

Read more reviews on Azure instruments by clicking here. For more about the latest Seal of Quality winners, see the SelectScience website.

Azure Biosystems Launches Azure Cielo Dx for In-vitro Diagnostic Use

Press Releases

Dublin, Calif. – October 27, 2021 –Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and cell biology, announced today that the company is now authorized to distribute and service the Azure Cielo™ Dx in European Union (EU) countries for in vitro diagnostic (IVD) use. The Azure Cielo™ 3 Dx and the Azure Cielo™ 6 Dx, are real-time PCR systems for 3 and 6 channel nucleic acid detection, respectively, and conform to the EU’s In Vitro Diagnostic Directive (IVDD).  These medical device products are also registered with the US FDA for in vitro diagnostic use and have been available since June 2021.

Since launching in March of 2020, Azure Cielo™ has become part of research labs across world, meeting the global demand for real-time PCR systems. The sensitivity and reproducibility of the Azure Cielo™ have driven the success of Azure Biosystem’s first instrument dedicated to the genomics workflow.

The Azure Cielo™ 3 Dx and the Azure Cielo™ 6 Dx,  are controlled by a 10.3” touch screen interface, with intuitive software that makes setting up runs and checking run status easy. The compact instrument can transfer data via USB, ethernet or Wi-Fi. For run setup and data analysis, the system comes with Azure Cielo Manager software which offers a complete workflow solution for real time PCR run setup and analysis.

The Azure Cielo™ Dx systems are expected to begin shipping to Europe in October 2021.

For more information, contact, (925) 307-7127